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Quinoline-Conjugated Ruthenacarboranes: Toward Hybrid
Drugs with a Dual Mode of Action
Marta Gozzi,[a] Blagoje Murganic,[b] Dijana Drača,[b] John Popp,[a] Peter Coburger,[a]
Danijela Maksimović-Ivanić,[b] Sanja Mijatović,[b] and Evamarie Hey-Hawkins*[a]
The role of autophagy in cancer is often complex, ranging from
tumor-promoting to -suppressing effects. In this study, two
novel hybrid molecules were designed, containing a ruthena-
carborane fragment conjugated with a known modulator of
autophagy, namely a quinoline derivative. The complex closo-
[3-(η6-p-cymene)-1-(quinolin-8-yl-acetate)-3,1,2-RuC2B9H10] (4)
showed a dual mode of action against the LN229 (human
glioblastoma) cell line, where it inhibited tumor-promoting
autophagy, and strongly inhibited cell proliferation, de facto
blocking cellular division. These results, together with the
tendency to spontaneously form nanoparticles in aqueous
solution, make complex 4 a very promising drug candidate for
further studies in vivo, for the treatment of autophagy-prone
glioblastomas.
1. Introduction
Polyhedral molecular boron-carbon clusters (carboranes) of
type closo-C2B10H12, nido-[C2B9H12]
  , nido-[C2B9H11]
2  and their
metal complexes, are already well-established scaffolds in the
medicinal inorganic chemistry.[1] By far the most extensively
studied application of carboranes in medicine is their use as
high-boron carriers for boron neutron capture therapy (BNCT),[2]
followed by pharmacophores in drug design[3a,b] and radio-
imaging agents.[4,5] Regardless the particular type of cluster,
carborane-containing molecules and complexes have been
intensively studied for targeting cells and tissues within the
central nervous system (CNS),[6a–d] because they are able to
efficiently cross the blood-brain-barrier (BBB, the “brain keep-
er”), thanks to the presence of hydridic B  H bonds, which make
the cluster highly hydrophobic.[7]
During our investigations on the medicinal chemistry of
ruthena- and molybdacarboranes,[8–10] we showed that these
complexes spontaneously self-assemble in aqueous solutions,
forming nanoparticles.[10] Using bovine serum albumin (BSA) as
nanocarrier system allows to control the size of the nano-
particles to ca. 100 nm,[9] which falls within the optimal size
range for application of nanoparticle-based drug delivery
technologies, in terms of cellular uptake and clearance
pathways.[11] Thus, this spontaneous property of the metal-
lacarborane fragment is well-suited for designing novel chemo-
therapeutic agents to target those types of tumor, where nano-
sized chemotherapeutics might provide superior efficacy com-
pared to non-nano-sized drug formulations, due to the
characteristics of the tumor itself, as proposed recently, for
example, for brain tumors of the glioblastoma type (GBM).[12]
The latter are in fact tumors characterized by extensive and
irregular vasculature, which makes them optimal targets for
drug delivery systems that can exploit the “enhanced perme-
ability and retention effect” (EPR) of cancer cells with respect to
healthy cells, thus promoting tumor-selectivity of the treatment.
The big advantage in using metallacarboranes is that there is
no need for engineering the nanoparticles, they are sponta-
neously formed. In this work, the metallacarborane unit should
act, therefore, as pharmacophore and delivery system.
We chose to combine an [(η6-arene)Ru]2+-carborane unit
with a 1-aza-naphtalene-based organic residue, commonly
known as quinoline (Figure 1). Quinoline derivatives possess a
plethora of biological activities,[13a,b] which have prompted the
development of numerous drugs, ranging from antiparasitic (e.g.
chloroquine and its ferrocene analogue ferroquine), to antiviral
(e.g. saquinavir), antibacterial (e.g. ciprofloxacin), anti-inflamma-
tory (e.g. quinoline alkaloids), antioxidant (e.g. quinoline glyco-
conjugates), antineoplastic (e.g. irinotecan), and many
others.[14a–c] The specific type and position of substituents on the
heterocycle influence the physicochemical and pharmacologic
properties of the quinoline-containing molecules, and thus
modulate the activity of the drug, as reported for example by
Natarajan et al. in a structure-activity relationship (SAR) study on
the influence of side chain length and quinolyl nitrogen pKb on
the antimalarial activity of chloroquine.[15] Combinations of a
ruthenium(II)-arene fragment with chloroquine (CQ) or 8-
hydroxyquinoline (8-HQ) derivatives have been reported by
many in the literature (Gobec et al., Mitrović et al., Kubanik et al.,
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Glans et al., Movassaghi et al., Martinez et al.), showing modu-
lation of the biological activity with respect to the two scaffolds
alone, for potential applications as chemotherapeutic agents in
different types of tumors (e.g. leukemia, colorectal, lung and
cervical cancers),[16a–c,17,18] and as antiparasitic agents.[19a–c]
For the present work, we were particularly interested in the
activity of substituted quinolines as modulators of macro-
autophagic processes,[20–22] often simply called autophagy. The
latter is an ensemble of physiologic catabolic processes,[23,24]
which break cytosolic proteins and organelles down to their
building blocks, e.g. amino acids, in response to a plethora of
stressors including starvation, oxidative stress and pathogens,
and act also as a quality control system, to ensure homeostatic
functions and organelle turnover. Strong evidence has been
collected in the last 20 years which supports a dual role of
autophagy in cancer, either in tumor suppression or in tumor
promotion, depending on the specific cancer type and the
stage.[25,26] Thus, the complex plethora of phenomena which
underlie the cellular autophagic response, has become today a
very attractive biochemical target for anti-cancer therapies,
although the fundamental genetic mutations and biochemical
processes are, for many cases, not fully elucidated:[26] its
modulation was shown to promote (re)sensitization of cancer
cells to the applied treatment, either cytotoxic agents (chemo-
therapy) or radiation therapy, for cases of pancreas, breast and
prostate cancers, and gliomas.[27a–d]
CQ and its derivative hydroxychloroquine (HCQ) are known
inhibitors of autophagy,[20,21] used in the clinics to treat GBM
tumors, typically in combinatorial therapies together with the
alkylating agent temozolomide (TMZ), and contribute, in some
cases, to extend survival prognoses in patients affected by
these aggressive, autophagy-prone tumors.[28] The N,N-(8-
hydroxyquinoline)methyl-substituted benzylamine JLK1486 has
been reported to inhibit cellular proliferation in B16F10 skin
melanoma cells, via induction of cytodestructive autophagy.[29]
The styrylquinoline LV-320 was found to block the autophagic
flux, and thus impair cellular viability, in several breast cancer
cell lines, in a dose-dependent manner.[30]
Here, we aimed at studying the modulation of the biological
activity of a ruthenacarborane fragment upon conjugation with
a quinoline residue, specifically investigating the modulation of
the cellular autophagic response after treatment with the
ruthenacarborane alone, or with its quinoline conjugates. As
linker, a carboxylic acid ester was chosen, and its stability
toward hydrolysis at physiologic pH (7.4) was investigated. The
aqueous self- and co-assembly behavior of the ruthenacarbor-
ane ester 4 and the corresponding free acid (3), with and
without BSA, was studied via Nanoparticle Tracking Analysis
(NTA). The complexes were screened against a panel of cancer
cell lines, including human breast adenocarcinoma (MCF-7) and
human glioblastoma (LN229) cells. Their mechanism of action
was further investigated via flow cytometry, fluorescence micro-
scopy and wound healing assay, and the presence of autophagy
marker LC3B (microtubule-associated light chain protein 3B)
was evaluated via western blot analysis.
2. Results and Discussion
2.1. Synthesis and Characterization
Ruthenacarborane complex 3 (i.e. free acid) was synthesized in
two steps from closo-1-(CH2COOH)-1,2-C2B10H11 (1) (Scheme 1). A
methylene spacer between the cluster and the carboxylic acid
group was preferred over no spacer, i.e. the formic acid-
substituted closo-1-(COOH)-1,2-C2B10H11, due to the well-known
tendency of an electron-withdrawing carboxylic acid group to
spontaneously undergo decarboxylation, when attached directly
to the cluster, which could also, prospectively, impair biological
stability of the complex. Deboronation of 1 proceeded smoothly
in KOH/EtOH at reflux overnight, or, alternatively, with excess NaF
in EtOH/H2O (3 :2 (v/v)) at 90°C, in an analogous way as described
by El-Zaria et al. for guanidine-substituted closo-ortho-
carboranes.[31] The same approach was successfully applied for the
deboronation of the quinolin-8-yl ester 6, which gave straightfor-
ward access to nido-carborane(  1) 7 as its sodium salt, in 64%
yield. 3 was obtained via salt-metathesis from the dithallium salt
of 2 and [{(η6-p-cymene)RuCl(μ-Cl)}2], which is a standard approach
to ruthenacarboranes,[32a,b] in low yield (36%) after tedious
separation via column chromatography. Activation of the carbox-
ylic group of 3 with di-tert-butyl dicarbonate (Boc2O), in CH2Cl2/
pyridine, followed by reaction with sodium quinolin-8-olate (or [(7-
chloroquinolin-4-yl)oxy]butanol-1-ate), yielded ruthenacarborane
esters 4 and 5, in 18% and 21% yield, respectively. 8-
hydroxyquinoline (8-HQ) was chosen due to the plethora of
studies which combine a ruthenium(II)-arene fragment with 8-
HQ,[17,18,33] and [(7-chloroquinolin-4-yl)oxy]butanol because of its
structural similarity to CQ, but still suitable for the synthesis of an
ester bond. The low yields of isolated final products can be
attributed, at least partially, to the instability of the carborane-
bound ester bonds on chromatography columns (see also ester 6
(19%)), as we have frequently observed in our group, for both
ester and amide bonds (see for example ref. [34]). Interestingly,
the carboxylic group of 1 and 3, which are structurally both closo
species, could be activated under analogous conditions
(Scheme 1), to form an ester bond, with both an aromatic (4, 6)
and an alkyl (5) alcoholate. Reaction of the dithallium salt of 7
Figure 1. Molecular structure of quinoline-conjugated ruthenacarboranes 4
and 5, synthesized in this work (right). The lead organic structure (chloro-
quine, CQ) is shown on the left. The 1-aza-naphthalene heterocycle is
highlighted in blue.
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with [{(η6-p-cymene)RuCl(μ-Cl)}2] failed to give access to the
desired ruthenacarborane ester, but yielded instead 3, i. e. the free
acid, and a second carborane-free ruthenium(II)-arene complex,
identified via 1H NMR spectroscopy as chlorido(8-quinolinato-
k2N,O)(η6-p-cymene)ruthenium(II) (Figure S1, SI), already reported
in the literature.[18]
1H and 11B NMR (CDCl3) spectroscopic analysis of the
deprotonation of 7 with thallium ethanolate (TlOEt, step c in
Scheme 1) confirmed quantitative conversion to the dithallium
salt without cleavage of the ester bond, whereas no NMR
spectrum of the dithallium salt of 2 (i. e. free acid) could be
measured in CDCl3, due to its very low solubility (Figures S2 and
S3, SI). Changing the base from TlOEt to the bulky lithium
bis(trimethylsilyl)amide (LiHMDS) or changing the stationary
phase from silica gel to neutral alumina for the chromatographic
separation of the crude product yielded again only 3. So, it is not
a nucleophilic base, nor the purification method, which
completely cleaves the ester bond, but probably cleavage
already occurs during the complexation reaction itself, when the
Ru2+ center can be coordinated by the nitrogen and oxygen
atoms of the quinoline ring, besides the C2B3 face of the
dicarbollide cluster.
The unsymmetrical substitution of the cluster carbon atoms
introduces chirality to the molecule, or metal complex, as
evidenced in the 1H NMR spectra of 2–5 and 7. The two α-
methylene protons (H1 for 2 and 7, H11 for 3–5) are magnetically
not equivalent, due to the presence of the C2B3 chiral plane,
and thus appear as two doublets, with geminal coupling
constants of 16–17 Hz (Figure S4, SI). All compounds were
synthesized as racemic mixtures and used as such. 1H NMR
signals for the ruthenacarborane unit are almost identical in 3,
4 and 5, in CDCl3. The same holds for the
11B NMR spectra,
which shows that modifications of the cluster-bound carboxylic
acid group have little to no influence on the electron
distribution throughout the cluster. Crystallographic study of 1
and 3 showed that the two fragments [C2B10H11] and [RuC2B9H10]
are isolobal species, with 3 derived from formal replacement of
the B(3)  H group of 1 with the [Ru(η6-p-cymene)]2+ fragment,
which results in a distorted closo structure (Figure 2). The p-
cymene ligand in 3 is bent toward the boron atoms of the C2B3
face, which results in higher deviation from coplanarity of the
aromatic C6 and the B5H5 ring (6.84(7)°, Table 1), and a higher
tilt angle between C6 and the C2B3 ring (8.19(7)°), with respect
to the corresponding unsubstituted complex [3-(η6-p-cymene)-
3,1,2-RuC2B9H11] (5.11(9)° and 6.25(7)°).[8] This is partially due to
the stronger trans influence of the boron atoms compared to
Scheme 1. Synthetic approaches to target ruthenacarborane complexes 4 and 5, from closo-carborane derivative 1. (a) i) KOH (3.5 eq.), EtOH, reflux, 21 h; ii)
HClaq. (b) NaF (5.0 eq.), EtOH/H2O 3 :2 (v/v), 90 °C, 18 h. (c) i) TlOEt (3.0 eq.), THF,   35 °C to rt, 2 h; ii) [{(η6-p-cymene)RuCl(μ-Cl)}2] (0.5 eq.), CH2Cl2(deg.),   65 °C to
rt, 18 h; iii) HClaq. (d) Boc2O (1.5 eq.), 8-hydroxyquinoline (for 4, 6) or [(7-chloroquinolin-4-yl)oxy]butan-1-ol (for 5) (1.25 eq.), NaNH2 (1.25 eq.), CH2Cl2/pyridine
10 :1 (v/v),   35 °C to rt, 19 h.
Figure 2. Molecular structures of 1 (left) and 3 (right). Thermal ellipsoids at
50% probability level. Labelling of selected atoms is given.
Full Papers
3ChemMedChem 2019, 14, 1–15 www.chemmedchem.org © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Dienstag, 19.11.2019
1999 / 151639 [S. 3/15] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
carbon,[35] but also to electronic repulsion between O(1)/O(2)
(carboxy group) and the π system of the arene ligand, rather
than to steric crowding, as observed instead by Welch and co-
workers for ether-substituted ruthenacarboranes[36] (in the case
of 3, the lowest intramolecular H···H distances (H(17A)···H(7)
2.668(1) Å; H(17A)···H(8) 2.762(1) Å) are larger than the sum of
their van der Waals radii).
The packing is stabilized by intermolecular hydrogen bonds
(H(2X)···O(1) for 1 and 3, H(3A)···O(1) for 1). One molecule of 1
forms two hydrogen bonds with two other molecules, resulting
in a “polymer”-like 3D network, whereas one molecule of 3
forms a centrosymmetric dimer, which is often observed for
carboxylic acids (Figure S8, SI).[37]
Thus, of the two synthetic approaches tested for the
synthesis of ruthenacarborane esters, the activation of the free
carboxylic group of complex 3 (step d in Scheme 1) with Boc2O
in CH2Cl2/pyridine, followed by reaction with an aryl or alkyl
alcoholate, gave straightforward access to the desired quinoline
esters 4 and 5. That one can make use of one unique building
block, such as the carboxylic acid 3, to attach different types of
substituents (e.g. aryl or alkyl groups), represents an enormous
advantage in the synthetic chemistry of metallacarboranes, and
is in fact a broadly used approach, both for full- and half-
sandwich metallacarboranes, alike.[38a–c] To the best of our
knowledge, this is the first report on the use of a carboxylic
acid-functionalized ruthenacarborane as building block for the
synthesis of esters, designed for triggering a specific biological
response. The successful activation of the carboxylic acid group
in complex 3 paves the way for the synthesis of a multitude of
rationally designed complexes, which might also incorporate,
for example, biomolecules, such as specific peptides for target-
vector recognition mechanisms.
2.2. Stability Studies
Stock solutions of sparingly water-soluble compounds for in vitro
cell cultures are usually prepared in DMSO, ethanol or methanol,
and stored frozen over months, provided that the compound
shows the necessary chemical stability (no or minimal ligand
dissociation, in the case of metal complexes). 3 and 4 were found
to be stable in water-containing DMSO-d6 solution, in air, for
over a month. No changes were detected in either 1H or 11B{1H}
NMR spectra (Figures S5 and S6, SI). 5 showed no changes in the
11B{1H} NMR spectrum, but a second set of signals for the [(7-
chloroquinolin-4-yl)oxy]butanol-1-yl group appeared in the 1H
NMR spectrum, right after dissolution in DMSO-d6, and remained
constant in shift and intensity over one month (Figure S7, SI).
These signals cannot be attributed to free 4-{(7-chloroquinolin-4-
yl)oxy}butanol-1-ate, but rather indicate the presence of a second
tautomer (ca. 5% at 25 °C), which is common in polar solvents
for quinoline-containing groups.[39]
Following our recent investigations on the self-assembly
behavior of ruthenacarborane complexes in aqueous solutions
at physiologic pH,[10,9] the behavior of free acid 3 and ester 4 in
aqueous solution was studied via UV-vis spectroscopy and
Nanoparticle Tracking Analysis (NTA) in phosphate-buffered
saline (PBS)/DMSO mixtures (pH 7.4). UV-vis spectroscopy is a
useful tool to follow the ester hydrolysis over time, when a UV-
(vis)-active chromophore is present (in the case of 4, the
quinoline ring). Experiments were carried out at room temper-
ature (23 and 25 °C, for UV-vis and NTA, respectively), to
simulate the conditions of the working solutions used for cell
cultures, and at 37 °C (UV-vis), to simulate the conditions of
incubation of cells.
4 shows one broad absorption band in the range 250–
320 nm, right after dissolution in PBS/DMSO (black curve,
Figure 3, left), which is blue-shifted with respect to the
corresponding band of free 8-hydroxyquinoline (8-HQ) (Fig-
ure S9, SI). This broad band overlaps with two sharp transition
bands, which do not shift with temperature (λmax=300 and
314 nm). These transitions could be due to a plethora of
phenomena, including LMCT/MLCT transitions, Rayleigh and
Raman scattering. A detailed explanation of this phenomenon
was, however, beyond the scope of this study. A sharp
absorption band (ɛ>1.2) for λmax=229 nm was also present
(π!π* or n!π*), which however was not taken into account for
following the hydrolysis of the ester bond, due to partial
overlapping with buffer absorptions (Figure S10, SI). Over 23–
26 hours, at least two processes are simultaneously at play in the
PBS/DMSO solution of 4, both at 23 and 37 °C. One is the
hydrolysis of the ester bond, the other the shift in the equilibrium
between prototropic species of 8-HQ, as reported for 8-HQ in
aqueous solutions at neutral pH.[39,40] 8-HQ alone in PBS/DMSO in
fact also showed an evolution profile over time, at 23 and 37 °C,
alike (Figure 3, right). For 4, the bands at λmax 240 and 256 nm,
characteristic of the quinoline heterocycle, show a clear evolution
profile, either linear or not, depending on the temperature, even
after complete hydrolysis. In addition, in the spectrum of 4,
scattering from the ruthenacarborane fragment is evident in the
region 240–320 nm (Figure 3, left). At 23 °C hydrolysis of the ester
Table 1. Selected bond lengths (Å) and angles (°) for 1 and 3.
1 3
C  C(cluster) 1.651(5) 1.665(3)
B  B[a] 1.776(6) 1.779(5)
B  C(cluster)[a] 1.710(5) 1.720(4)
Ru  C(C2B3 face)
[a] – 2.183(2)
Ru  B(C2B3 face)
[a] – 2.205(3)
B(3)  C(C2B3 face)
[a] 1.705(5) –
B(3)  B(C2B3 face)
[a] 1.754(6) –
Ru  Ctd1[b] – 1.725(3)
Ru  Ctd2[b] – 1.614(3)
Ru  C(p-cymene)[a] – 2.231(3)
H(2X)···O(1) 1.698(6) 1.865(3)
H(3A)···O(1) 2.516(1) –
Deviation from coplanarity[c] – 6.84(7)
[a] Average value. [b] Ctd1=centroid of the C6H4 ring of the p-cymene
ligand. Ctd2=centroid of the C2B3 face of the dicarbollide ligand. [c]
Deviation from coplanarity of the arene (p-cymene) and dicarbollide
ligands was measured between the least-squares plane formed by the C6H4
ring of the arene ligand and the least-squares plane formed by the lower
boron belt (B5H5) of the cluster, as reported previously.
[24]
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bond proceeds linearly with time (Figure 3, top left), and can be
easily monitored following the increase in intensity of the band
at λmax 240 nm, and the red shift of the broad band at 250–
320 nm to 290–340 nm, which belong to free 8-HQ (Figure S9,
SI). An analogous red shift of the broad extinction band,
following hydrolysis, is observed at 37 °C (Figure 3, bottom left).
At 37 °C, however, the evolution of the band at λmax 240 nm is
not linear with time. At 23 °C hydrolysis is pronounced after 5 h,
and is complete after 23 h, whereas at 37 °C, already after 2.5 h
hydrolysis has reached completion.
These results thus suggest that the ester bond of 4
undergoes hydrolytic cleavage, in aqueous solution at pH 7.4,
which supports the use of an ester bond between the
ruthenacarborane fragment and the quinoline group as cleav-
able linker under physiologic conditions. Based only on these
data, hydrolysis rate constants for 4 were not calculated, due to
the contribution of two distinct phenomena to the extinction
bands at λmax 240 and 256 nm and the scattering component
from the ruthenacarborane fragment itself (240–320 nm).
NTA measurements of 3 and 4 in PBS showed that the two
complexes spontaneously form self-assemblies of nanometer
size, with high polydispersity and in high concentration (106–
107 particles mL  1, Figure 4). Upon addition of 10 equivalents of
bovine serum albumin (BSA), a significant increase of particle
concentration was observed, with respect to 3 (or 4) and BSA
alone (Figure 4). Furthermore, the polydispersity of the samples
was greatly reduced to a mostly monomodal dispersion, in an
analogous way as we recently extensively described for
unsubstituted complexes of the type [3-(η6-arene)-3,1,2-
RuC2B9H11].
[9] When changing the molar ratio from 10 :1 to 1 :1
(BSA:metallacarborane), the control over size distribution of the
self-assemblies is completely lost in the case of the BSA  3
system, whereas for BSA  4 it is partially retained, although the
concentration of co-assemblies is 10× lower than in the
corresponding samples with a 9-fold excess of BSA. This
supports our previous investigations, in that an excess of BSA is
needed for size stabilization of the BSA  ruthenacarborane co-
assemblies.[9] The mean particle size for BSA  ruthenacarborane
(10 :1) systems is very similar for the two complexes, with values
of 65–70 nm. Based on these results, and on our recent studies
on related ruthenacarboranes, we suggest that the spontaneous
self-assembly in aqueous solutions, with and without BSA, is a
property of the metallacarborane fragment itself, regardless of
the presence (and type) of cluster-bound substituents.
Thus, free acid 3 and esters 4 and 5 show sufficient chemical
stability in wet DMSO for application in cell cultures. Moreover,
Figure 3. Time-resolved UV-vis spectra of 4 (left) and 8-HQ (right) in PBS solution, at 23 °C (top) and 37 °C (bottom). 3 in PBS solution is also shown, as
reference. Vol% DMSO is 1% for all samples. λmax 240 and 256 nm (characteristic of the quinoline group) are marked in all spectra. For 4 at 23 °C (top left), the
black arrow indicates the time evolution of the band at λ240. Red indicates bands characteristic of 4 only, purple of 8-HQ only. * highlights the two sharp
transitions for 4. For 4, the red arrow indicates the time-evolution (decrease) of the sharp band at λ314, the red-to-purple arrow indicates the red shift of the
broad band, from 250–320 nm (characteristic of 4, red) to 290–340 nm (characteristic of 8-HQ, purple).
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3 and 4 showed spontaneous self- and co-assembly behavior
with and without BSA, in PBS, suggesting that the “self-
organizing” nanoparticles/nano-carriers display properties that
might be beneficial for targeting tumor tissues which are
characterized by a high degree of vasculature, i. e. prone to
high degree of angiogenesis, such as GBM.
2.3. In vitro Cell Colorimetric Assays
In our previous studies on the biological activity of ruthenacar-
borane complexes,[8] we found evidence of insurgence of
cytoprotective autophagy in the MCF-7 cell line after incubation
with the complex [3-{η6-(4-Me-1-COOEt-C6H4)}-3,1,2-RuC2B9H11].
This was suppressed, when the cells were exposed to dual
treatment with the ruthenacarborane and the lysosomal
autophagy inhibitor chloroquine (CQ), thus potentiating the
moderate anti-proliferative activity of the ruthenium complex
alone. In the present study, the ruthenacarborane and the
quinoline fragments are covalently bound (4 and 5). Thus, care
must be taken when comparing their biological activities with
those of our previous studies, even with the same cell line,
because the covalent vs. non-covalent combination of drugs
might imply different mechanisms of action in the cell.[44] Here,
we studied the in vitro activity of ruthenacarborane 3, i. e. free
acid, and its 8-hydroxyquinolyl (4) and 4-{(7-chloroquinolin-4-yl)
oxy}butanol-1-yl (5) esters, against a panel of cancer cell lines
(B16 mouse melanoma, A375 human skin melanoma, MCF-7
human breast adenocarcinoma, LN229 human glioblastoma,
U251 human glioma). Human fibroblast cell line MRC-5, murine
microglial cell line BV-2 as well as peritoneal exudate cells
(Mph), were chosen as models for non-malignant cells. Follow-
ing the NTA results (see above), cell viability assays were
performed using two different drug formulations, namely with
and without pre-incubation with BSA, as we reported recently.[9]
On the one side, we wanted to test the possible modulation of
the biological activity, depending on dispersity of the nano-
particles (monomodal or polymodal). On the other side, we
wanted to assess the reproducibility of the viability data, under
either controlled (with BSA) or uncontrolled (without BSA)
conditions, in two sets of independent assays. The DMSO stock
solutions of complexes 3–5 were either directly diluted with cell
culture medium to the desired final concentrations (1 to
100 μM), or first incubated for 0.5–1 h with a 9-fold excess of
BSA in PBS, and then diluted with cell culture medium. Cells
were exposed to 3–5 for 72 h, after which cell viability was
determined via 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide (MTT) and crystal violet (CV) assays, in parallel
(Table 2). Cisplatin was also tested as reference. Discrepancies in
the calculated IC50 values obtained from the two assays (MTT or
CV) were found for all tested complexes, as well as for cisplatin
against the B16 cell line (Table 2).
In general, the IC50 values for all compounds of the BSA-free
formulations are in good accordance with those for the
respective BSA-stabilized formulations, in both assays (Table 2,
Figure S11, SI).
Compound 3 decreased cell viability in a dose-dependent
manner in A375, B16 and MCF-7 cell lines (Table 2, Figure S11,
SI), with values of 18–23 μM (CV). Significant is that, when
comparing 3 to the corresponding unsubstituted complex [3-
(η6-p-cymene)-3,1,2-RuC2B9H11],
[8] the simple introduction of a
carboxylic acid group at a C-vertex of the dicarbollide cluster (3)
was sufficient to promote sensitization of the B16 cell line to
the treatment. At this stage, it is premature to venture an
hypothesis on the reason for this, since further studies would
be necessary, and also because cellular uptake mechanisms and
intracellular binding of boron-containing drugs in B16 cells still
remain poorly understood and are partly controversial.[5,41] The
glioblastoma (LN229) and glioma (U251) cell lines were found
to be resistant to treatment with 3, the free acid (IC50>100 μM
for U251, 80.0 μM for LN229), and 5, the alkyl quinoline-based
ruthenacarborane ester (IC50>100 μM for U251, 82.5 μM for
LN229), for the concentration range tested (Table 2). Conversely,
4, the aryl 8-hydroxyquinolyl ester, effectively impaired cell
Figure 4. Size distribution of 3 and BSA  3 (left), and 4 and BSA  4 (right) in PBS, from NTA measurements. Ratio BSA:metallacarborane was 10 :1 or 1 :1. [3]=
[4]=20 μM. [BSA]=20 (BSA1) or 200 (BSA10) μM. Vol% DMSO is 1% in all samples. Dilution factors are the same for all samples. Samples were measured 3.5–
6 h after preparation. The respective blanks (BSA alone) are also shown. Standard deviation (SD) for particle concentration is �2.3–3.1×107 (samples with 3)
and �1.5–2.4×107 (samples with 4) particles mL  1, for particle size �5–16 nm.
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viability of both U251 and LN229 cell lines (Figure S11, SI), at
IC50 concentrations of 33–45 μM, depending on assay and
formulation type (Table 2). For comparison of 4 with a known
active compound, U251 and LN229 cells were treated with CQ,
already approved in the clinics as autophagy inhibitor for
combinatorial treatments for GBM.[28] As expected, CQ also
affected cell viability in both U251 and LN229 cells (Figure S12,
SI; IC50=30–50 μM), confirming that in the tested glioblastoma
and glioma cell lines autophagy inhibition plays a central role in
the decrease of cell viability (IC50 3~5>4~CQ). Furthermore,
the type of quinoline ester, either aryl (4) or alkyl (5), showed
major influence on the activity of the drug against U251 and
LN229 cells, which could be related to different efficacy of the
complexes in disrupting the autophagosomes,[24] which are
formed in the cytoplasm following an autophagic response,
similar as observed by Natarajan et al. for a small library of
chloroquine derivatives.[15] Exposure of transformed non-malig-
nant human fibroblast MRC-5 and murine microglial BV-2 cell
lines showed similar sensitivity to the treatment with all
compounds, which could be ascribed to their high proliferative
rate and might indicate that drugs affected cellular proliferation
(Table 2, Figure S13, SI).
Treatment of primary non-malignant mouse macrophages
(Mph), that are non-dividing cells, with 3–5 showed higher
impairment of cell viability (2× higher) for 3 in comparison to 4
and 5 (Table 2, Figure S13, SI), with IC50 values (CV) of 49, 94
and >100 μM for 3, 4 and 5, respectively. This suggests a
central role of the quinoline fragment of 4 and 5 in promoting
cell survival. That a treatment targeting autophagy shows
selectivity toward tumor cells rather than healthy cells, is highly
desirable, since questions have been raised on the possible side
effects of such a therapeutic treatment, because autophagy is a
physiological process, which is found in many different
(healthy) tissues of the body.[42] Further studies in vivo will be
necessary to assess the selectivity of the ruthenacarborane
complexes, against a broader panel of healthy cells and tissues.
Overall, viability data showed good reproducibility (standard
deviation <10%) for the three compounds tested, with both
drug formulations, i. e. BSA-free and BSA-stabilized. The fact
that these self-assembled BSA  ruthenacarborane nano-carriers
do not greatly affect the in vitro biological activity of the
ruthenacarborane complex itself, is a rare property, when
compared to, for example, the engineered PEG-based nano-
sized delivery systems used by Sadler and co-workers for
loading the poorly water-soluble half-sandwich Ru2+ and Os2+
complexes [(η6-p-cymene)Ru(1,2-dicarba-closo-dodecaborane-
1,2-dithiolate)],[43] or to Rutherrin, a Ru2+ polypyridyl complex
(TLD1433) conjugated with transferrin, in a 1 :1 ratio, which is
currently under clinical evaluation as photosensitizer for the
treatment of GBM.[44]
It remains to be elucidated, whether the
BSA  ruthenacarborane formulation might be beneficial in vivo,
where formulations of nanoparticles with low polydispersity
might enhance cellular uptake, or exploit the EPR effect to
promote tumor penetration and selectivity.
2.4. Flow Cytometry, Fluorescence Microscopy, Wound
Healing Assay
To evaluate the possible mechanism of action of the ruthena-
carboranes, flow cytometric analysis was carried out on two
physiologically and morphologically different cell lines, namely
the MCF-7 and the LN229 cell lines, with 3 and 4. Complex 5,
although it showed the lowest toxicity of the series against the
mouse macrophages, was not investigated further because it
was inefficient against glioma and glioblastoma cell lines.
LN229 was used as model for aggressive, autophagy-prone
malignant GBM,[45] whereas MCF-7 was selected for consistency
with our previous studies.[8,9] We aimed at supporting the
observations made from in vitro colorimetric assays, concerning
the effects of the conjugation with a quinoline residue of the
ruthenacarborane fragment on proliferation, survival and death
mechanisms of the selected cell lines. All investigations
discussed below for 3 and 4 were performed using the BSA-free
formulation, unless otherwise stated.
Table 2. IC50 values for 3–5 from MTT and CV cell viability assays. Standard deviations for each IC50 value are given.
IC50 [μM]
Cells
Compound Assay A375 B16 MCF-7 U251 LN229 BV-2 MRC-5 Mph
3 MTT 9.7�1.1 19.4�0.9 7.7�0.8 >100 80.1�4.0 64.7�0.7 44.2�1.6 –b
CV 18.7�1.8 21.1�2.0 22.9�1.4 >100 80.0�7.7 68.2�1.3 58.5�0.3 49.1�1.2
BSA  3a MTT 22.5�0.5 23.8�0.1 14.2�2.3 >100 >100 66.7�0.8 35.5�3.6 –b
CV 35.0�7.1 32.0�1.7 23.3�7.9 >100 >100 71.5�1.2 56.3�0.9 50.0�5.0
4 MTT 11.9�1.2 20.4�2.1 15.9�0.2 46.2�1.9 42.4�3.9 8.7�0.1 3.9�0.1 –b
CV 14.9�2.1 24.5�2.1 16.9�1.1 45.1�0.8 33.4�3.5 9.2�0.1 4.9�0.1 94.0�7.7
BSA  4 MTT 18.4�0.8 15.8�1.0 15.4�0.4 40.4�1.4 37.4�3.2 9.4�0.1 4.3�0.1 -
CV 17.2�1.3 21.1�2.7 16.6�0.7 40.7�2.5 31.1�8.1 9.9�0.1 5.0�0.1 100.0�0.1
5 MTT 43.4�0.3 9.5�1.8 15.5�1.5 >100 86.7�3.0 12.3�0.1 >100 -
CV >100 33.7�2.9 34.1�0.5 >100 82.5�7.6 >100 >100 >100
BSA  5 MTT 39.1�1.9 6.7�1.8 17.4�0.8 >100 84.5�0.7 11.4�0.1 >100 –b
CV 95.1�6.9 32.7�12.9 37.5�3.5 >100 90.2�0.9 >100 >100 >100
Cisplatin MTT 3.3�0.4 6�0.4 3.0�0.5 0.4�0.1 4.1�0.4 –b –b –b
CV 3.7�0.1 10.9�1.2 3.5�0.2 0.8�0.3 4.1�0.6 –b –b –b
a BSA  ruthenacarborane indicates incubation of 3–5 with a 9-fold excess BSA, before dilution with cell culture medium. b “–“ stands for not tested.
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Figure 5. Results from flow cytometric and fluorescence microscopy analysis, and wound healing assay of MCF-7 cells incubated (72 h) with 3 and 4 at 20 μM.
(A) CFSE staining (left panel) and wound healing assay (right panel); (B) AnnV/PI double staining; (C) DAPI-stained cells observed under fluorescence
microscope (magnification X200). Arrows indicate apoptotic cells; (D) ApoStat staining; (E) AO staining. Experiments were run in triplicate. One representative
example per each experiment is shown. For each staining protocol, the respective control (untreated cells) is also shown. (FL1, green channel; FL2, orange
channel; FL3, dark red channel).
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2.4.1. MCF-7 Cell Line
Treatment of MCF-7 cells with either 3 or 4 (20 μM, 72 h)
showed inhibition of cellular proliferation accompanied by
inhibited cell migration, proved by wound healing assay (Fig-
ure 5A, left and right panels for 3 and 4, respectively). In
parallel, modest increase of late apoptotic (Ann+/PI+) cells, with
respect to the control (Figure 5B) was observed. When 4 was
applied as BSA  4 formulation, no significant changes were
found in the anti-proliferative activity, compared to the BSA-
free formulation (Figure S16, SI), which supports the observa-
tions from the colorimetric assays. However, enhanced gran-
ularity of the MCF-7 cells that was found upon treatment with 4
or BSA  4 (Figure S17, SI), illustrated that cells efficiently
internalized nanoparticles of 4 (or BSA  4), or that nanoparticles
of 4 bind to the cell surface, similarly as we observed previously
for the ruthenium complex [3-{η6-(biphenyl)}-3,1,2-RuC2B9H11].
[9]
Confirming our previous data,[8] microscopic evaluation of
DAPI (4’,6-diamidino-2-phenylindole) stained cells showed
sparse morphological signs of apoptosis for both 3 and 4
(Figure 5C).
While 3 was found to induce caspase activation, caspase-
independent apoptosis was observed for 4 (Figure 5A and D,
right panel), indicating that combination of the quinoline
residue with the ruthenacarborane fragment influenced the
basic mechanism of action of the ruthenium complex (free acid
3). This might be due to the interference of autophagic
responses with caspase regulation, since caspase-dependent
apoptosis and autophagy are known to share regulatory
components, e.g. BCL2 gene, and were also shown to act as
mutual inhibitors.[46] Finally, compound 3 strongly amplified
autophagic processes (Figure 5E, left panel). However, in
contrast to the complex [3-{η6-(4-Me-1-COOEt-C6H4)}-3,1,2-
RuC2B9H11], which induced cytoprotective autophagy,
[8] treat-
ment of MCF-7 cells with 3 and either one of the two inhibitors
of autophagy CQ or 3-methyladenine (3-MA), resulted in
restoration of cellular viability, indicating that in this circum-
stances autophagy has a cytodestructive role and, thus,
contributes to the cytotoxicity of the drug (Figure S15, SI).
According to this, compound 4 suppressed autophagy and was
less efficient against MCF-7 cells than 3 (Figure 5E, right panel).
2.4.2. LN229 Cell Line
When glioblastoma cells (LN229) were treated with an IC50 dose
of 4 (72 h), the observed number of acidic vesicles was
significantly lower than in the same cells treated with an IC50
dose of 3 (Figure 6A). Thus, in accordance with the viability
data, it is obvious that 4 targets cytoprotective autophagy in
LN229 cells. Concordantly, the expression of microtubule-
associated protein light chain 3B (LC3B), which forms a stable
association complex with the membrane of autophagosomes,
was significantly diminished upon exposure to 4, confirming
once again that 4 efficiently inhibited autophagy.[47] This result
is in accordance with the previous observation by Mauthe et al.
that chloroquine inhibits autophagy by impairing autophago-
some fusion with lysosomes.[20] In parallel, an increased number
of both early (Ann+/PI  , from 0.9% to 9.0%) and late apoptotic
(Ann+/PI+, from 7.4% to 35%) cells were detected after
exposure to 4, with respect to the control (Figure 6B). DAPI
staining of LN229 cells incubated with 4 showed several typical
morphological features of apoptosis, such as apoptotic bodies,
condensed chromatin, shrunken nuclei (Figure 6C). These
apoptotic events were accompanied by strong inhibition of
cellular proliferation (CFSE staining, Figure 6D, left panel):
according to the intensity of fluorescence, cells exposed to 4
stayed undivided, oppositely to control, indicating that inhib-
ition of cellular division precedes cell death. Additionally, cells
exposed to 3, and especially 4, showed inhibited motility
(Figure 6D, right panel). Significantly lower number of cells after
the treatment with compounds 3 and 4 was also evident from
the scratch test, confirming again the affected proliferative
potential besides cell death. Taking this into account, it is not
surprising that non-malignant MRC-5 and BV-2 cell lines showed
analogous sensitivity to the treatment with 3 and 4 in the
viability tests.
Thus, 4 acts in vitro as a hybrid molecule against malignant
glioblastoma cells (LN229), inhibiting cellular division and, in
parallel, cytoprotective autophagy, which supports the rational
drug design idea of this work. It is obvious from the recent
literature that modulation of autophagy is an attractive
therapeutic approach for treatment of GBM, for inducing (re)
sensitization to cytotoxic or cytostatic drugs.[12,28,45,48] It needs to
be said that a full elucidation of the cause–effect relationship
between autophagy and cancer cells survival or death would be
a very ambitious scope at this point. In fact, the exact
mechanisms which trigger and regulate the autophagic
response in a specific tissue, healthy or diseased, as well as
some steps of the catabolic pathway itself, are today still under
dispute, as discussed recently by Yin et al.,[46] mostly because of
the intrinsic difficulty of studying these processes in their
“native” state.[49]
3. Conclusions
Ruthenacarborane complex 3 was synthesized in two steps
from closo-1-(CH2COOH)-1,2-C2B10H11 (1), in low yield (36%). The
free carboxylic acid group of 3 could be easily activated using
Boc2O in CH2Cl2/pyridine to yield ruthenacarborane esters 4 and
5, after reaction with the respective alcoholate species, the aryl
8-hydroxyquinolinate (for 4) and the alkyl 4-[{(7-chloroquinolin-
4-yl)oxy}butan]-1-olate (for 5). The hydrolytic cleavage of the
ester bond of 4 at pH 7.4 was complete after 2.5 h (37 °C) or
after 23 h (23 °C). The non-covalent interaction of 3 or 4 with a
9-fold excess of BSA spontaneously formed nano-sized particles
with low polydispersity, which did not affect the biological
activity profiles of 3 and 4 alone. Complex 4 affected cell
viability of human glioblastoma and glioma cell lines (LN229
and U251) at concentrations of 33–45 μM, whereas both 3 and
5 were inactive against the same cell lines. This means that
both the presence of a quinoline residue and its specific nature
(aryl in 4 vs. alkyl in 5) directly affected the anti-cancer activity.
Full Papers
9ChemMedChem 2019, 14, 1–15 www.chemmedchem.org © 2019 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
These are not the final page numbers! ��
Wiley VCH Dienstag, 19.11.2019
1999 / 151639 [S. 9/15] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
Moreover, the presence and type of substituents at the C-
cluster vertices plays a central role in the biological activity of
the ruthenacarborane fragment against the MCF-7 cell line,
being able to affect the basic mechanism of action at the
cellular level (see 3 vs. 4 vs. [3-(η6-p-cymene)-3,1,2-RuC2B9H11]).
This nicely supports one of the main motivations of using
carborane clusters for bioactive compounds, in that substitution
at the cluster vertices allows to fine-tune the properties of
potential drug candidates. Flow cytometric analysis on MCF-7
and LN229 cell lines, together with western blot data, gave
convincing evidence that 4 effectively inhibits autophagy, either
cytodestructive (in MCF-7) or cytoprotective (in LN229), and,
concomitantly, exerts a strong anti-proliferative effect on the
LN229 cell line, acting thus, in the latter case, as hybrid
molecule with dual mode of action in vitro.
Thus, 4 is a very promising potential drug candidate for
application in the treatment of glioblastomas, since it combines
favorable biological activities (anti-proliferative effects and
inhibition of autophagy) with the spontaneous self-aggregating
properties in aqueous solutions, which might be beneficial for
selectively targeting angiogenesis-prone tumors in vivo, such as
GBM. Compound 4 is now undergoing further evaluation of the
biological activity and of the pharmacokinetics of ester
hydrolysis in our laboratories, for further assessing its activity in
comparison to approved treatments for GBM, and for determin-
ing the feasibility of its application in vivo.
Figure 6. Results from flow cytometric and fluorescence microscopy analysis, wound healing assay and western blot analysis of LN229 cells incubated (72 h)
with 4, at 40 μM. (A) AO staining (left panel) and western blot (right panel). Cells incubated (72 h) with 3 are also shown, for comparison; (B) AnnV/PI double
staining; (C) DAPI-stained cells observed under fluorescence microscope (magnification X200). Arrows indicate apoptotic cells; (D) CFSE staining (left panel)
and wound healing assay (right panel). Experiments were run in triplicate. One representative example per each experiment is shown. For each staining
protocol, the respective control (untreated cells) is also shown. (FL1, green channel; FL2, orange channel; FL3, dark red channel).
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Experimental Section
Methods and Instrumentation
Chemicals were used as purchased. 1-(CH2COOH)-1,2-C2B10H11 (1)
and [(7-chloroquinolin-4-yl)oxy]butanol were synthesized as pre-
viously reported,[15,50] and their purity was assessed via NMR
spectroscopy and elemental analysis. Single crystals of 1 were
obtained from a saturated diethyl ether solution, at 0 °C, in about
three days. Syntheses and characterization data of 6 and 7 are
given in the Supplementary Information. All manipulations were
carried out in a dry nitrogen or argon atmosphere using standard
Schlenk techniques, unless otherwise stated. All manipulations
involving thallium(I) compounds were performed wearing personal
protective equipment as prescribed in the material safety data
sheet (MSDS), and thallium(I)-containing waste was disposed
according to regulations. Solvents were purified and stored as
indicated in the Supporting Information. Thin-layer chromatogra-
phy (TLC) was carried out on precoated silica glass plates (Merck
Silica Gel 60 F254) or on precoated alumina plates (Merck Alumina,
pH neutral, 70–230 mesh). Visualization of the compounds on TLC
plates was achieved by means of an iodine chamber, or by
treatment with a solution of PdCl2 (1 wt% in MeOH). Column
chromatography was carried out on silica gel (0.035–0.070 mm,
60 Å), or on alumina (pH neutral, 70–230 mesh). Semi-inert column
chromatography was performed using degassed stationary phase
and solvents, and flushing the column with nitrogen for 10 min,
before column packing.
NMR spectra were acquired at room temperature with a Bruker
AVANCE III HD 400 spectrometer. 1H (400.13 MHz) and 13C{1H}
(100.16 MHz) NMR spectra were referenced to tetramethylsilane
(TMS) as internal standard. 11B (128.38 MHz) NMR spectra were
referenced to the unified Ξ scale.[51] For the discussion of NMR data,
α and β indicate the two cluster-bound methylene protons. Mass
spectrometry measurements were carried out with an ESI-MS Bruker
ESQUIRE 3000 (Benchtop LC Iontrap) spectrometer, or Synapt G2-Si
spectrometer (Waters GmbH, Eschborn, Germany). FT-IR spectra were
obtained with a PerkinElmer system 2000 FTIR spectrometer,
scanning between 400 and 4000 cm  1. Elemental analyses were
performed with a Hereaus VARIO EL oven. X-ray data for 1 and 3
were collected with a GEMINI CCD diffractometer (Rigaku Inc.), using
Mo-Kα radiation (λ=0.71073 Å), T=130(2) K and ω-scan rotation.
Data collection and refinement data are given in Table S1 (SI).
Absorption corrections were performed with SCALE3 ABSPACK.[52]
The structures were solved by direct methods (1) or by dual-space
methods (3), with SHELXS and SHELXT-2014, respectively.[53] Structure
refinement was done with SHELXL-2016[54] by using full-matrix least-
square routines against F2. All non-hydrogen atoms were refined
with anisotropic thermal parameters and the HFIX command was
used to locate all hydrogen atoms. The C2 unit of the carborane
cluster was located with bond length analysis. The pictures were
generated with the programs Diamond (version 3.2)[55] or Mercury
(version 3.10).[56] CCDC 1915974 (1) and 1915975 (3) contain the
supplementary crystallographic data for this paper. UV-vis absorption
spectra were measured with a PerkinElmer UV/VIS/NIR Lambda 900
spectrometer, equipped with tungsten-halogen and deuterium
lamps, using quartz cuvettes (V=3 cm3, l=10 mm). Spectra were
recorded in the range 240–600 nm, at 1.0 nm resolution. Nano-
particle Tracking Analysis data were recorded using a NanoSight
LM10 (Malvern Instruments Ltd, Worcestershire, UK), containing a
sample chamber of about 0.25 mL, and equipped with a 532 nm-
laser, a microscope LM14B and a camera sCMOS. The NTA 3.0
analytical software (NanoSight Ltd) was used for both capture and
processing. Acquisition and processing parameters were optimized
for each sample and the respective blank. Flow cytometry analyses
were carried out on a CyFlow® Space instrument (from Sysmex Partec
GmbH, Germany), equipped with five lasers (405, 488, 532, 561, 638–
640 nm) and a charge-coupled device (CCD) camera for sample flow
monitoring. Results were analyzed with PartecFloMax® software, as
reported previously.[57]
Syntheses
rac-[M][nido-7-(CH2COOH)-7,8-C2B9H11] (2) (M=K (K[2]) or Na (Na
[2]))
Method A. Potassium hydroxide (625 mg, 11.13 mmol, 4.5 eq.) was
dissolved in dry EtOH (30 mL). 1 (500 mg, 2.47 mmol, 1.0 eq.) was
added in one portion and the mixture was brought to reflux for
21 h. The solvent was then removed in vacuo, leaving an off-white
solid. The residue was taken up with H2O (4 mL) and acidified to
pH 2 with HClaq (20 vol%). The water phase was concentrated to
1 mL, cooled to 5 °C and filtered. The white solid was washed with
n-hexane (10 mL, 15 min sonication), filtered off, redissolved in Et2O
(13 mL) and filtered through Celite. The volatiles were removed,
and the colorless solid was dried in vacuo for 12 h (50 °C, 10  3
mbar), yielding pure K[2] (Yield: 338 mg, 59%).
Method B. Alternatively, 1 (57 mg, 0.28 mmol, 1.0 eq.) was added to
EtOH/H2O (5 mL, 3 : 2 (v/v)), under nitrogen atmosphere, forming a
suspension. NaF (58.8 mg, 1.4 mmol, 5.0 eq.) was added in one
portion, and the mixture was heated to 90 °C. Reaction progress
was followed via 11B{1H} NMR spectroscopy. After 18 h, heating was
stopped, and the mixture was left to cool down to room temper-
ature. Amberlite (IR120) was added and the mixture was stirred for
another hour, then filtered and the solvent evaporated to dryness.
The white residue was taken up in Et2O (2 mL), filtered through
Celite and evaporated to dryness. The crude product was washed
three times with n-hexane (3×4 mL, 3×15 min sonication), filtered
and dried in vacuo for 16 h (50 °C, 10  3 mbar), yielding Na[2] (Yield:
21 mg, 35%). NMR data for Na[2] are identical to those of K[2].
K[2]. 1H NMR (CD3CN): δ (ppm)=   2.56 (1H, br s, endo-H),   0.63–
2.48 (br, B  H), 1.81 (1H, br s, Ccluster  H), 2.31 (1H, d,
2JHH=15.9 Hz,
H1α), 2.59 (1H, d, 2JHH=16.2 Hz H
1β). 11B NMR (CD3CN): δ (ppm)=
  10.6 (2B, d, 1JBH=135 Hz),   14.2 (1B, d,
1JBH=159 Hz),   17.2 (1B,
d, 1JBH=152 Hz),   18.4 (2B, d,
1JBH=152 Hz),   22.2 (1B, d,
1JBH=
144 Hz),   33.5 (1B, dd, 1JBH=127, 49 Hz)   37.2 (1B, d,
1JBH=135 Hz).
13C{1H} NMR (CD3CN): δ (ppm)=15.6 (s, C
1), 44.5 (s, Ccluster  H), 66.2 (s,
Ccluster), 174.1 (s, C
2). IR (KBr; selected absorptions): ~v (cm  1)=3436
(br m, νOH), 2963 (m, νCHcluster), 2597 (m, νBH), 2570 (s, νBH), 2529 (s,
νBH), 1709 (s, νC=O), 1262 (s, νCO), 1103 (s), 1030 (s), 802 (s, νBB). ESI-
MS (pos.): m/z=483.1948 (100%, [2 M+Na]+). Anal. calcd for
C4H13B9O2K (231.14): C, 20.93; H, 5.71. Found C, 21.29; H, 5.92.
closo-[3-(η6-p-Cymene)-1-(CH2COOH)-3,1,2-RuC2B9H10] (3)
Deprotonation of the nido-carborane(-1) precursor. K[2] (338 mg,
1.47 mmol, 1.0 eq.) was dissolved in dry THF (10 mL) under argon
atmosphere, protected from light. The solution was cooled to   35 °C
and TlOEt (0.32 mL, 4.40 mmol, 3.0 eq.) was added in one portion,
causing immediate precipitation of a bright yellow solid. The mixture
was stirred at   35 °C for 30 min, then at room temperature for an
additional 1.5 h. Stirring was stopped, the supernatant THF solution
was filtered, and the residue was washed with dry EtOH (8 mL) and
n-hexane (5 mL). The yellow solid (Tl[Tl2]) was dried in vacuo for 3 h
and used directly, without further purification.
Complexation reaction. [{(η6-p-cymene)RuCl(μ-Cl)}2] (300 mg,
0.49 mmol, 0.33 eq.) and Tl[Tl2] (1.47 mmol, 1.0 eq.) were thoroughly
mixed at   65 °C under argon atmosphere, protected from light.
Degassed CH2Cl2 (8 mL) was added and the red-orange mixture was
left stirring for 18 h to warm up to room temperature. HClaq
(20 vol%, 0.1 mL) was added and the mixture was stirred for 40 min,
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after which Celite was added, and the volatiles were removed in
vacuo. The residue was purified via column chromatography on silica
gel (length=5 cm, diameter=2.5 cm) in air, using n-hexane/ethyl
acetate/acetic acid (1 :1:0.01 (v/v) !1:3:0.01 (v/v)!acetone). Two
bands were collected, one yellow band containing pure 3 (Rf=0.22
in n-hexane/ethyl acetate, 1 :3 (v/v)), one red-orange band, contain-
ing a mixture of nido-carborane 2 and [{(η6-p-cymene)RuCl(μ-Cl)}2]
(Rf=0.09 in n-hexane/ethyl acetate, 1 :3 (v/v)). 3 was obtained as air-
stable pale-yellow solid (75 mg, 36%). Recrystallization from chloro-
form afforded pale yellow platelets, suitable for X-ray diffraction
analysis. 3 is soluble in acetone, THF, acetonitrile and DMSO,
moderately soluble in chloroform and dichloromethane.
1H NMR (CDCl3): δ (ppm)=0.82–3.91 (br, B  H), 1.31 (3H, d,
3JHH=
6.9 Hz, H8 or H9), 1.33 (3H, d, 3JHH=6.9 Hz, H
8 or H9) 2.35 (3H, s, H10),
2.92 (1H, hept, 3JHH=6.9 Hz, H
7), 3.23 (1H, d, 2JHH=16.7 Hz, H
11α),
3.43 (1H, d, 2JHH=16.7 Hz, H
11β), 4.71 (1H, s, Ccluster  H), 5.74 (1H, d,
3JHH=6.1 Hz, H
2 or H6), 5.87 (1H, d, 3JHH=6.1 Hz, H
3 or H5), 5.89 (1H,
d, 3JHH=6.2 Hz, H
3 or H5), 5.93 (1H, d, 3JHH=6.0 Hz, H
2 or H6). 11B NMR
(CDCl3): δ (ppm)=1.6 (2B, d,
1JBH=138 Hz),   3.4 (1B, d,
1JBH=
147 Hz),   7.8 (1B, d, 1JBH=144 Hz),   8.9 (1B, d,
1JBH=137 Hz)   10.0
(1B, d, 1JBH=143 Hz),   14.4 (1B, d,
1JBH=169 Hz),   18.3 (1B, d,
1JBH=
163 Hz),   19.7 (1B, d, 1JBH=182 Hz).
13C{1H} NMR (CDCl3): δ (ppm)=
18.8 (s, C10), 22.3 (s, C8 or C9), 23.2 (s, C8 or C9), 31.3 (s, C7), 51.6 (s,
C11), 54.7 (s, Ccluster  H), 64.6 (s, Ccluster), 88.1 (s, C
3 or C5), 88.5 (s, C3 or
C5), 90.8 (s, C2 or C6), 91.6 (s, C2 or C6), 102.1 (s, C4), 112.2 (s, C1) 175.9
(s, C12). IR (KBr; selected vibrations): ~v (cm  1)=3436 (br m, νOH), 2963
(m, νCHcluster), 2597 (m, νBH), 2570 (s, νBH), 2529 (s, νBH), 1709 (s, νC=O),
1262 (s, νCO), 1103 (s), 1030 (s), 802 (s, νBB). ESI-MS (pos.): m/z=
425.2389 (100%, [M]+). Anal. calcd for C14H27B9O2Ru (425.73): C,
39.50; H, 6.39. Found C, 39.09; H, 6.20.
closo-[3-(η6-p-Cymene)-1-(quinolin-8-yl-acetate)-3,1,2-RuC2B9H10]
(4)
Compound 3 (63.0 mg, 0.15 mmol, 1.0 eq.) was dissolved in dry
CH2Cl2/pyridine (5.5 mL, 10 :1 (v/v)) under argon atmosphere and
cooled down in an ice bath (H2O-NaCl). Di-tert-butyl-dicarbonate
(Boc2O, 51 μL, 48.4 mg, 0.22 mmol, 1.5 eq.) was added in one
portion. After 5 min, the cooling bath was removed, and the
mixture was stirred at room temperature for 2 h. In parallel, 8-
hydroxyquinoline (26.9 mg, 0.18 mmol, 1.25 eq.) was dissolved in
dry CH2Cl2 (5.5 mL) and cooled to   35 °C. NaNH2 (7.2 mg,
0.18 mmol, 1.25 eq.) was added in one portion. After 5 min the
cooling bath was removed, and the mixture was stirred at room
temperature for 1.5 h, until gas evolution ceased. The CH2Cl2/
pyridine solution of Boc-activated acid 3 was then slowly added via
cannula to the quinoline-containing mixture, and the reaction
mixture was stirred at room temperature for 19 h. Degassed
alumina (ca. 0.5 g) was added to the mixture and volatiles were
removed in vacuo. The residue was purified via semi-inert filtration
over a short pad of alumina (length=3 cm; diameter=2.5 cm),
using degassed CHCl3!CHCl3/ethyl acetate (7 : 1 (v/v))!ethyl
acetate. One yellow band (Rf=0.93 in CHCl3) was collected and
evaporated to dryness, yielding 4 as a yellow-orange powder
(15.3 mg, 18%). 4 was obtained as air-stable solid, soluble in
dichloromethane, chloroform, acetone and DMSO.
1H NMR (CDCl3): δ (ppm)=0.90–3.80 (br, B  H), 1.29 (3H, d,
3JHH=
3.4 Hz, H8 or H9), 1.31 (3H, d, 3JHH=3.4 Hz, H
8 or H9), 2.33 (3H, s, H10),
2.90 (1H, hept, 3JHH=6.9 Hz, H
7), 3.22 (1H, d, 2JHH=16.6 Hz, H
11α),
3.42 (1H, d, 2JHH=16.6 Hz, H
11β), 4.69 (1H, s, Ccluster  H), 5.72 (1H, d,
3JHH=6.1 Hz, H
2 or H6), 5.85 (1H, d, 3JHH=6.1 Hz, H
3 or H5), 5.87 (1H,
d, 3JHH=6.2 Hz, H
3 or H5), 5.90 (1H, d, 3JHH=6.0 Hz, H
2 or H6), 7.42
(1H, dd, 3JHH=8.3, 4.2 Hz, H
19), 7.48–7.54 (2H, m, H14 and H16), 7.70
(1H, dd, 3JHH=6.2, 3.4 Hz, H
15), 8.16 (1H, dd, 3JHH=8.3,
4JHH =1.5 Hz,
H18), 8.92 (1H, dd, 3JHH=4.2,
4JHH=1.5 Hz, H
20). 11B NMR (CDCl3): δ
(ppm)=1.6 (2B, d, 1JBH=136 Hz),   3.4 (1B, d,
1JBH=146 Hz),   7.8
(1B, d, 1JBH=134 Hz),   8.9 (1B, d,
1JBH=139 Hz)   9.9 (1B, d,
1JBH=
138 Hz),   14.4 (1B, d, 1JBH=153 Hz),   18.2 (1B, d,
1JBH=181 Hz),
  19.7 (1B, d, 1JBH=193 Hz).
13C{1H} NMR (CDCl3): δ (ppm)=18.9 (s,
C10), 22.3 (s, C8 or C9), 23.2 (s, C8 or C9), 31.3 (s, C7), 34.9 (s, C11), 54.6
(s, Ccluster), 66.5 (s, Ccluster  H), 88.1 (s, C
3 or C5), 88.5 (s, C3 or C5), 90.9
(s, C2 or C6), 91.6 (s, C2 or C6), 102.2 (s, C4), 112.2 (s, C1), 121.0 (s, C14),
121.8 (s, C16), 125.7, 126.2, 135.9, 141.3 (s, C17), 147.5 (s, C21), 150.4 (s,
C20), 152.1 (s, C13), 168.6 (s, C12). IR (KBr; selected vibrations): ~v (cm  1)
=3439 (w, νOH), 2964 (m, νCHcluster), 2529 (w, νBH), 1754 (s, νC=O), 1369
(m), 1261 (s, νCO), 1148 (s), 1098 (s), 1025 (s), 801 (s, νBB). ESI-MS(  ):
m/z=590.4365 (100%, [M+Cl]  ). Anal. calcd for C23H32B9NO2Ru
(555.23): C, 49.97; H, 5.83; N, 2.53. Found C, 50.03; H, 6.02; N, 2.74.
closo-[3-(η6-p-Cymene)-1-[(7-chloroquinolin-4-yl)oxy]butyl ace-
tate)-3,1,2-RuC2B9H10] (5)
Compound 5 was synthesized in an analogous way as described for
4, from 3 (100 mg, 0.23 mmol, 1.0 eq.), 4-{(7-chloroquinolin-4-yl)
oxy}butanol (73.9 mg, 0.29 mmol, 1.25 eq.), Boc2O (81 μL, 76.9 mg,
0.35 mmol, 1.5 eq.) and NaNH2 (11.5 mg, 0.29 mmol, 1.25 eq.). The
product was purified as described for 4, using CHCl3!CHCl3/
acetone (7 :1 (v/v)). The crude product from the column (yellow-
orange band, Rf=0.96 in CHCl3) was washed with n-hexane (2×
3 mL; 2×10 min sonication) to yield pure 5 (32.7 mg, 21%) as an
air-stable yellow-orange powder.
1H NMR (CDCl3): δ (ppm)=0.29–3.45 (br, B  H), 1.30 (3H, d,
3JHH=
3.9 Hz, H8 or H9), 1.32 (3H, d, 3JHH=4.0 Hz, H
8 or H9), 1.86–2.00 (2H,
m, H14 or H15), 1.99–2.10 (2H, m, H14 or H15), 2.34 (3H, s, H10), 2.91 (1H,
hept, 3JHH=6.9 Hz, H
7), 3.22 (1H, d, 2JHH=16.6 Hz, H
11α), 3.42 (1H, d,
2JHH=16.6 Hz, H
11β), 4.18 (2H, t, 3JHH=6.4 Hz, H
13), 4.22 (2H, t, 3JHH=
6.1 Hz, H16), 4.69 (1H, s, Ccluster  H), 5.73 (1H, d,
3JHH=6.1 Hz, H
2 or H6),
5.86 (1H, d, 3JHH=6.1 Hz, H
3 or H5), 5.89 (1H, d, 3JHH=6.2 Hz, H
3 or
H5), 5.92 (1H, d, 3JHH=6.2 Hz, H
2 or H6), 6.71 (1H, d, 3JHH=5.3 Hz, H
18),
7.43 (1H, dd, 3JHH=8.8,
4JHH =1.9 Hz, H
23), 8.00 (1H, d, 4JHH=1.8 Hz,
H21), 8.13 (1H, d, 3JHH=8.9, H
24), 8.72 (1H, d, 3JHH=5.2, H
19). 11B NMR
(CDCl3): δ (ppm)=1.5 (2B, d,
1JBH=113 Hz),   3.3 (1B, d,
1JBH=
139 Hz),   7.8 (1B, d, 1JBH=144 Hz),   8.9 (1B, d,
1JBH=137 Hz),   10.0
(1B, d, 1JBH=142 Hz),   14.4 (1B, d,
1JBH=152 Hz),   18.2 (1B, d,
1JBH=
156 Hz),   19.7 (1B, d, 1JBH=210 Hz).
13C{1H} NMR (CDCl3): δ (ppm)=
18.7 (s, C10), 22.2 (s, C8 or C9), 23.1 (s, C8 or C9), 27.6 (s, C14 or C15),
28.0 (s, C14 or C15), 31.3 (s, C7), 54.5 (s, Ccluster), 55.8 (s, C
11), 66.3 (s, C13),
66.4 (s, Ccluster  H), 67.9 (s, C
16), 88.1 (s, C2 or C6), 88.4 (s, C3 or C5), 90.8
(s, C3 or C5), 91.5 (s, C2 or C6), 100.9 (s, C18), 102.1 (s, C4), 112.1 (s, C1),
119.8 (s, C25), 123.3 (s, C24), 126.4 (s, C23), 127.9 (s, C21), 135.6 (s, C22),
149.7 (s, C20), 152.5 (s, C19), 161.4 (s, C17), 168.5 (s, C12). IR (KBr;
selected vibrations): ~v (cm  1)=3408 (w, νOH), 2924 (m, νCHcluster), 2497
(s, νBH), 1743 (s, νC=O), 1342 (m), 1325 (m), 1274 (s, νCO), 1238 (s, νCO),
1123 (s), 1086 (s), 789 (s, νBB). ESI-MS(  ): m/z=325.1775 (100%, [4-
(7-Cl–C9H5N)-O-(CH2)4-COOCH2+Cl]
  ), 517.2159 (42.5%, [M–(p-
cymene)]  ). Anal. calcd for C27H39B9ClNO3Ru (659.42): C, 49.18; H,
5.96; N, 2.12. Found C, 49.23; H, 5.98; N, 2.20.
Stability studies
NMR spectroscopy. To determine the stability in biocompatible
organic solvents, 3–5 (each ca. 3 mg) were dissolved in water-
containing DMSO-d6 (0.6 mL) in air at room temperature, and
periodically frozen (4–5 °C) and unfrozen. The solutions were
analyzed with 1H and 11B{1H} NMR spectroscopy over a period of one
month.
UV-vis spectroscopy. Stock solutions of 3, 4 and 8-hydroxyquinoline
(8-HQ) in distilled DMSO were freshly prepared before use ([3]=
2.11 mM; [4]=6.56 mM; [8-HQ]=25.76 mM). An aliquot of the
DMSO stock solution of 3, 4 or 8-HQ was added to 3 mL PBS
solution, so that the final concentration was 20 μM. DMSO content
was adjusted to 1 vol% (considering the amount of DMSO from the
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stock solutions) before addition of the ruthenacarborane, in all
samples. Time-resolved UV-vis spectra of 4 were measured, over a
period of 26 h at room temperature (23�1 °C) and at 37�0.3 °C to
follow hydrolysis of the ester bond of 4 at physiologic pH (7.4).
PBS/DMSO solutions of 3 and 8-HQ were also measured, as
references. All measurements were corrected by subtracting the
blank (PBS+1 vol% DMSO). Experiments were run in duplicate.
Nanoparticle Tracking Analysis (NTA). 3 and 4 were analyzed via NTA
to study the modulation of self-assembly behavior in PBS/DMSO
mixture (pH 7.4), with and without BSA, in an analogous way as
described previously.[9] Samples of 3 and 4 in PBS/DMSO were
prepared as described above for UV-vis measurements. The solutions
were measured 30 min after preparation. Samples of BSA  3 and
BSA  4 were prepared with two different BSA:ruthenacarborane
ratios, namely 10 :1 and 1 :1. Stock solutions of BSA in PBS ([BSA]PBS=
1.128 mM) were diluted to final concentrations of 200 or 20 μM with
PBS (Vfin=5 mL), then an aliquot of the stock solution of 3 or 4 was
added, so that the final concentration of metallacarborane was
20 μM. Content of DMSO was adjusted to 1 vol% (considering the
amount of DMSO from the stock solutions) before addition of the
ruthenacarborane, in all samples. The solutions of
BSA  ruthenacarborane were measured 3.5–6 h after preparation.
BSA alone in PBS/DMSO was also measured, as blank, using the
same capture and processing parameters as for the respective
BSA  metallacarborane samples, for direct comparison. All NTA
measurements were performed at 25�0.1 °C. Each sample was
measured in five independent captures. The time of each capture
was set to 60 s.
Biological Studies
Cells were cultivated as described in the Supporting Information.
Preparation of drug solutions. DMSO stock solutions of 3–5, CQ and
3-MA were prepared at concentrations of 30 mM (3, CQ, 3-MA) or
50 mM (4, 5) and stored at   20 °C. Stock solution of cisplatin was
prepared in DMF (10 mM) immediately before use. A stock solution
of BSA in PBS was prepared at 1.28 mM concentration, and stored
at 4 °C in the dark. For application to cell cultures, serial dilutions of
3–5 or CQ were prepared in the cell culture medium, so that the
final concentration of the ruthenacarboranes (or CQ) was 1.6, 3.1,
6.3, 12.5, 25, 50 or 100 μM. Alternatively, 3 or 4 (DMSO stock
solution) were added to the BSA solution in PBS, always with a 10 :1
molar ratio of BSA to ruthenacarborane. The BSA  ruthenacarborane
solutions were incubated 0.5–1 h at room temperature, then
diluted with cell culture medium to the desired final concentra-
tions. Final concentrations of 3 and 4 were the same as for the BSA-
free formulation. Final DMSO was 0.02–0.5 vol%.
Colorimetric assays for cellular viability. Cells were exposed to
various concentrations (0–100 μM) of 3–5 (or BSA  3/4), CQ or
cisplatin for 72 h. For counting the number of attached (viable)
cells, cells were fixed with 4% (w/v) paraformaldehyde for 10 min
at room temperature, and subsequently stained for 15 min with
1 mol% crystal violet (CV) solution. Cells were then washed with tap
water, dried in air, and the CV dye was dissolved in 33% (w/v)
acetic acid solution. For the detection of mitochondrial respiration,
cells were cultivated in MTT staining solution (0.5 mgmL  1) for
approximately 1 h. The dye was then discarded, and the formed
formazan (purple) was dissolved in DMSO. The absorbance was
measured with an automated microplate reader at λmax 540 nm,
with the reference λmax 670 nm. Untreated cells or cells treated only
with BSA (control) were also measured, as reference for BSA-free
and BSA-containing drug formulations, respectively. For determi-
nation of the role of autophagy specific inhibitors, CQ or 3-MA,
were applied at a concentration of 20 μM and 0.5 mM, respectively,
and the cells were stained with CV dye. Cell viability is expressed as
percentage (%) relative to control (untreated cultures).[58] Experi-
ments were run in three independent replicates. Standard devia-
tions of the calculated IC50 mean values were within 10%. Non-
linear regression analyses of the obtained results was done using
GraphPad Prism software to calculate IC50 values.
Flow cytometry. For gaining better insights into the mechanisms of
action of the ruthenium complexes, MCF-7 and LN229 cells
incubated with an IC50 dose of 3 or 4, were analyzed via flow
cytometry. Several staining protocols were carried out in parallel, in
independent experiments: i) AnnV/PI for the detection of apoptotic
cell death, ii) AO for the detection of acidic vacuoles, iii) ApoStat for
checking caspase activation, iv) CFSE for detecting interference
with cellular proliferation, and v) DAPI for the detection of
morphological signs of apoptosis. Untreated cells or cells treated
only with BSA (control) were also measured, as reference for BSA-
free and BSA-containing drug formulations, respectively. 4 was
applied to the MCF-7 cells as either BSA-containing or BSA-free
formulation. Staining protocols are described in the Supporting
Information. Channels FL1 (green emission), FL2 (orange emission)
and/or FL3 (dark red emission) were used for fluorescence
detection, according to the specific staining agent. Sideward Scatter
(SSC) for MCF-7 cells treated with 4 or BSA  4 was also analyzed,
with respect to the control, for detection of shifts of cell granularity.
Experiments were run in three independent replicates.
Statistical analysis. Analysis of variance (ANOVA) followed with a
Student-Newman–Keuls test was used for significance of the
differences between treatments, and a p value less than 0.05 was
taken as statistically significant.
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